Skip to content

Per-Oral Cholangioscopy (POCS) in Liver Transplantation Patients

Per-Oral Cholangioscopy (POCS) in Liver Transplantation Patients - POCS in Liver Transplantation Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON55336
Enrollment
10
Registered
2020-09-08
Start date
2021-02-18
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-liver transplant BD strictures A clinical suspicion of post-liver transplant bile duct stricture(s). Biliary complications in post-liver transplant

Interventions

None listed

Sponsors

Boston Scientific Corporation
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Liver transplantation at least 1 month prior to POCS procedure 2. Abnormal Liver Function Tests (LFTs) and/or biliary obstructive symptoms 3. Prior cross-sectional imaging (MRI and/or US and/or CT) 4. Suspected anastomotic biliary stricture(s) 5. Diameter of bile ducts deemed sufficient to accommodate cholangioscopy system based on baseline imaging. 6. Willing and able to provide a written informed consent to participate in the study 7. Willing and able to comply with study procedures and follow-up schedule

Exclusion criteria

Exclusion criteria: 1. Contraindication for an ERCP per local standard of practice 2. Contraindication for POCS per local standard of practice 3. Prior treatment of biliary anastomotic stricture 4.

Design outcomes

Primary

MeasureTime frame
The primary endpoint of this study is to evaluate the impact of the addition of POCS to same setting ERCP on the recommended management of post-liver transplantation biliary complications. • Recommended management options based on ERCP alone will be recorded immediately following the ERCP and before starting the POCS portion of the procedure; recommended management options based on ERCP and POCS combined will be recorded immediately following the POCS procedure. • Success is defined as different recommended management options based on ERCP alone versus on ERCP and POCS combined.

Secondary

MeasureTime frame
The following will be recorded as secondary outcomes during baseline and follow-up procedures: 1) Technical success: Ability to visualize the duct/lesion of interest and, if applicable, ability to obtain POCS-guided biopsy adequate for histopathology. 2) Serious Adverse Events (SAEs) including severity, onset, time to resolution, required interventions, relatedness to endoscopic devices and/or procedures and hospitalizations. 3) Number and type of biliary re-interventions. Re-interventions may include but are not limited to repeat ERCP, repeat POCS, ultrasonography, stent exchanges, balloon dilations and liver biopsy. 4) Confirmation at 3 months and at 12 months that recommended management at the index procedures was adequate. Confirmation of adequacy of patient management may be based on one or more of the following: • Resolution of symptoms • Improvement of LFTs compared to baseline • Confirmation of resolution of biliary complication with US/CT/MRI/MRCP imaging • Absence of unscheduled re-interventions during follow-up • Absence of SAEs during the follow-up period related to the original findings on POCS • Free passage of balloon sweep > 8-10mm 5) Relationship between endoscopic findings on POCS visualization during index procedure and refractory biliary strictures during follow-up. 6) Evaluation of surgeon of whether or not POCS impacted patient management post procedure.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)